Oral Rescue Drug Enters FDA Review, Bringing a Convenience Test for Hereditary Angioedema Treatment

For patients with hereditary angioedema, an attack is not an ordinary allergy, but an emergency that can quickly affect the face, abdomen, and even the airway. Whether a rescue drug can be carried at all times and used as soon as symptoms begin often determines whether an attack is brought under control or develops into a dangerous moment requiring medical intervention.

Pharvaris’s oral drug candidate deucrictibant immediate-release has had its new drug application accepted by the U.S. Food and Drug Administration, entering the formal review process. According to Investor's Business Daily, the FDA is scheduled to make a decision on whether to approve it by April 23, 2027. This makes deucrictibant an oral on-demand treatment option that could challenge the existing landscape of injectable rescue drugs.

Hereditary angioedema is a rare disease often associated with abnormal regulation of the complement and kinin systems. During an attack, vascular permeability increases, allowing fluid to seep into tissue and cause deep swelling; unlike typical histamine-mediated allergies, this type of swelling usually is not resolved with standard antihistamines or epinephrine. The development rationale for deucrictibant is to block the bradykinin B2 receptor, intervening downstream in the attack signaling pathway to reduce the continuation of the swelling response.

The clinical significance of this review lies in the fact that “rescue” treatment is especially time-sensitive. Existing on-demand therapies are mostly administered by injection or infusion, which may not be unworkable for experienced patients, but still create barriers involving training, supplies, pain, and use outside the home. If an oral drug can provide sufficiently fast and consistent relief early in an attack, convenience would be more than a commercial selling point and could change the rhythm of how patients manage attacks.

However, the currently public data are still insufficient to interpret this acceptance as a therapeutic victory. FDA acceptance of an application means the data package has met the formal and basic requirements to enter review; it does not mean the drug has already been deemed safe and effective. The subsequent review will still examine the speed of symptom relief in clinical trials, whether additional rescue treatment is needed, responses across different attack sites, and whether the safety data can support self-administration by patients at home.

The market reaction also reflects that the drug sits between expectation and uncertainty. The report noted that Pharvaris’s share price rose at one point after the news was announced, but turned lower by the close; investors clearly saw the potential market for an oral rescue drug, while also recognizing that review risks remain before approval and that, after approval, it would still face the real-world tests of existing injectable therapies, physician habits, and insurance coverage.

Therefore, the FDA’s decision in April 2027 will be more than a pipeline milestone for one company. It will also answer a more practical question in acute treatment for rare diseases: in conditions that require rapid suppression of symptoms, can an oral drug be both convenient and reliable. If the answer holds, the rescue toolkit for patients with hereditary angioedema may gain an option that is easier to use first; if the review requires more evidence, this convenience revolution will still have to return to the clinical data itself.